All In Biotech

Drug Trial Radar · NCT06668103

A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Firmonertinib

A Phase 2, Open-Label Study to Evaluate the Efficacy and Safety of ABSK043 Combined With Firmonertinib in Patients With EGFR Mutated Locally Advanced or Metastatic Non-small Cell Lung Cancer(NSCLC)

Last checked: Nov 19, 2026Latest source record: Dec 12, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

54

Planned (sponsor's estimate)

Start

Nov 25, 2024

Primary completion

Dec 30, 2027

Study completion Jun 30, 2028

Sponsor

Lead sponsor
Abbisko Therapeutics Co, LtdIndustry
Sponsor type
Industry
First posted
Oct 31, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label phase 2 study to evaluate the safety, tolerability and preliminary anti-tumour activity of ABSK043 in combination with Firmonertinib in patients with Epidermal Growth Factor Receptor-mutated (EGFRm+) locally advanced or metastatic NSCLC.

Conditions

  • Non-Small Cell Lung Cancer With EGFR Mutation

Interventions

  • ABSK043 in combination with FirmonertinibDrug

    Two potential dose levels :400 mg twice daily (BID) and 800 mg BID) of ABSK043 are prespecified and firmonertinib will be administered orally at a fixed dose of 80 mg once daily (QD). Patients in dose escalation cohort will receive the ABSK043, 400 mg BID and firmonertinib 80 mg QD as the starting dose for the combination therapy. Patients in dose confirmation cohort and dose expansion cohort will receive the recommended dose in dose escalation cohort and be evaluated for safety and preliminary anti-tumor activity of the combination therapy. After Cycle 1, patients will continue to receive combination therapy every 21 days until disease progression, death, loss to follow-up, withdrawal of consent, intolerable toxicity, investigator decision to discontinue treatment, or end of the study.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of DLTTime frame: At the end of Cycle 1 (each cycle is 21 days)
  2. AEsTime frame: From the time the patient signs the informed consent form throughout the study and up to 90 days after the last dose of ABSK043 or 30 days after the last dose of furmonertinib mesylate, whichever occurs first, up to 30 months.
  3. SAEsTime frame: From the time patients sign the informed consent form throughout the study and up to 90 days after the last dose of ABSK043 or 30 days after the last dose of furmonertinib mesylate, whichever occurs first, up to 30 months.
  4. AESIsTime frame: From the time patients sign the informed consent form throughout the study and up to 90 days after the last dose of ABSK043 or 30 days after the last dose of furmonertinib mesylate, whichever occurs first, up to 30 months.
  5. PFS rate at 12 monthTime frame: From the time patients receive the first dose of study drug to 12 months,assessed up to 30 months.

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Hanhui Cancer Hospital

    Hefei, Anhui, China · Not yet recruiting

  • Harbin Medical University Cancer Hospital

    Harbin, Heilongjiang, China · Not yet recruiting

  • Union Hospital Tongji Medical College Huzhong University of Science and Techology

    Wuhan, Hubei, China · Not yet recruiting

  • Jilin Cancer Hospital

    Changchun, Jilin, China · Not yet recruiting

  • Shanghai Chest Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.